ReviewNeurologic clinics2017
Lewy Body Disorders.
Review in Neurologic clinics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.BioMed research international · 2022Pooled it
- Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.Journal of Alzheimer's disease : JAD · 2023Trial
- Seven tesla MRI reveals amygdala and hippocampal subfield atrophy in dementia with Lewy bodies.Alzheimer's research & therapy · 2026Article
- A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.Nature medicine · 2026Article
- DOPA decarboxylase levels in the cerebrospinal fluid as a diagnostic marker of Lewy body disorders.Nature medicine · 2026Article
- Heterogeneity of dementia with lewy bodies: Insights from clinical presentations, neuropathology, and biomarkers.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Research models to study lewy body dementia.Molecular neurodegeneration · 2025Review
- Gray matter loss relates to dual task gait in Lewy body disorders and aging.Journal of neurology · 2024Article
- Article
- Dopamine levels determined in synthetic urine using an electrochemical tyrosinase biosensor based on ZnO@Au core-shell.RSC advances · 2023Article
- Sudden cardiac death in synucleinopathies.Journal of neuropathology and experimental neurology · 2023Article
- Dual-task gait and white matter hyperintensities in Lewy body diseases: An exploratory analysis.Frontiers in aging neuroscience · 2023Article
- Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.Journal of neurology · 2022Review
- Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies.Journal of Parkinson's disease · 2022Article
- Correlates of Conversion from Mild Cognitive Impairment to Dementia with Lewy Bodies: Data from the National Alzheimer's Coordinating Center.Journal of Alzheimer's disease : JAD · 2022Article
- Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease.Acta neuropathologica communications · 2021Article
- Basic Fibroblast Growth Factor 2-Induced Proteome Changes Endorse Lewy Body Pathology in Hippocampal Neurons.iScience · 2020Article
- Article
- Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies.Frontiers in synaptic neuroscience · 2020Review
- Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review.Neurology and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Dementia syndromes associated with Lewy bodies are subdivided into dementia with Lewy bodies (DLB), an underdiagnosed cause of dementia in the elderly, and Parkinson disease with dementia (PDD), cognitive impairment appearing in people diagnosed with Parkinson disease. Their neuropathologic substrates are the widespread distribution of aggregates of the protein α-synuclein in neurons in cortical brain regions, accompanied by variable Alzheimer pathology. Clinical features of DLB and PDD include distinctive changes in cognition, behavior, movement, sleep, and autonomic function. Diagnostic criteria for DLB and PDD incorporate these features. Current treatment options for DLB and PDD are symptomatic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.